Summary

Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH).[A180805] This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants.[L7363] It is marketed by Roche Pharmaceuticals and was granted FDA approval for the prophylaxis of transplant rejection in 1995.[A180826] In addition to the above uses, mycophenolate mofetil has also been studied for the treatment of nephritis and other complications of autoimmune diseases. Unlike another immunosuppressant class, the calcineurin inhibitors, MMF generally does n

Synonym type

Trade Names;synonym

Synonym

2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate CellCept MMF Munoloc Mycophenolic acid morpholinoethyl ester

Xref

DrugBank: DB00688   PharmGKB: PA450566   TTD: D04FBR  

CAS

128794-94-5

Formular

C23H31NO7

PubChem CID

CID 5281078

UNII

9242ECW6R0

ATC code

L04AA(S

Drug Type

small molecule

Drug status

approved

Source

PharmGKB;Drugbank